02/27/2026
Emerging research from the mycelial underground.
Published in Scientific Reports y e s t e r d a y ,
Adults with Post-Treatment Lyme Disease (PTLD) experienced:
π ~40β50% reduction in overall symptom burden
π ~50β60% reduction in depressive symptoms
π Significant improvements in sleep, fatigue, and pain
π Improved mental and physical quality of life
π Benefits sustained at 6 months.
What was the study you ask?
20 adults with well-documented PTLD underwent two supervised sessions (15β25 mg) with (and this is important!) Structured preparation and integration support and a 6 month follow up. No serious treatment-related adverse events were reported. Read the paper yourself for the rest of the deets.
This was small. Not randomized. Not definitive. But still exciting to see.
We know it takes an average of 17 years for research to reach clinical practice, so you wonβt be prescribed this by your P*P anytime soon. But even without using this or other psychedelics, it expands the conversation. It acknowledges what many of us already understand β that illness operates on dynamic, interrelated mind/body levels that profoundly shape infectious and chronic conditions alike.
PTLD affects an estimated 10β20% of patients after appropriate antibiotic treatment for Lyme disease. In clinical reality, that number likely underrepresents what we see β whether due to dismissal, misattribution, or patients not recognizing the Lyme connection themselves. There are currently no established treatments for PTLD.
When a condition has few effective options, thoughtful exploration matters β especially when it begins to validate what many of us have known about chronic Lyme for a long time:
Chronic, post-infectious illness is layered.
Itβs immune.
Itβs neurological.
Itβs psychological.
Itβs inflammatory.
Itβs deeply human.
Psilocybin and other psychedelics are not a magic answer. They are one of many tools that may help us reach complex, dynamic, and hard-to-access aspects of chronic illness β particularly where mood, pain perception, nervous system regulation, inner parts and inflammatory signaling intersect.